When the @who.int Executive Board discusses agenda item 14 on the draft updated global action plan on antimicrobial resistance (perhaps tomorrow), VMAT may crop up as a point of contention. @who.int #EB158

US pharma threaten to withhold products from Europe over prices giftarticle.ft.com/giftarticle/...

Contracts that Restrict Patent Filing or Impose Patent-Licensing Obligations www.keionline.org/bn-2025-4 @arianna-s.bsky.social @keiwashdc.bsky.social @who.int #IGWG4

Daniel Eisenkraft Klein and @arianna-s.bsky.social Equity in rhetoric and (in)action: a thematic analysis of Canada’s approach to intellectual property rights in pandemics gh.bmj.com/content/10/9...

Come join KEI's event at WHA78

New from @medslawpolicy.bsky.social , @ellenthoen.bsky.social - The People vs AbbVie: medicineslawandpolicy.org/2025/05/the-...

Read and wonder what Europe’s response has been so far. Hint: slash aid budgets: on.ft.com/4kfldmV The fallout @wemos.org

Proposal for Addition Of Risdiplam to WHO Model List Of Essential Medicines, for the treatment of Spinal Muscular Atrophy (SMA) www.who.int/groups/exper... @keiwashdc.bsky.social @arianna-s.bsky.social @jamielove.bsky.social @who.int

@arianna-s.bsky.social intervening for KEI at INB12 today.